An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone on a Wegovy prescription posted that their insurer (Aetna, with pharmacy benefits run by CVS Caremark) is asking for another "prior authorization" at the six-month point, and the pharmacy says the refill is held up while the doctor's office waits to finish paperwork. They’re worried they might lose coverage or that this will become a regular hassle. They want to know if others have had the same thing happen and why insurers suddenly ask for re-approval months into treatment. Wegovy is the brand name for semaglutide when it’s prescribed for weight loss. Semaglutide is a lab-made version of a natural gut hormone that helps reduce appetite and slow how fast the stomach empties, so people feel fuller and eat less. It’s a prescription shot you use regularly. Insurance companies don’t automatically cover it for everyone because it’s expensive and it’s a drug that’s sometimes used for different reasons, so they commonly use paperwork rules to decide who keeps getting it. What’s happening here — the six-month prior authorization — is a common insurance practice. Insurers often grant coverage initially, then require periodic rechecks to confirm the medication is still medically necessary. That can mean the insurer asks for updated records from the doctor: weight measurements, notes about whether the medicine is working, or evidence that other treatments were tried. The delay you’re seeing is likely administrative: the doctor’s office needs to send the requested documentation and the insurer needs to review it. In many cases people do get re-approval, but some do get denied if the required evidence isn’t provided or if the plan’s rules change. Why this matters: it affects adherence and cost. If the re-approval is delayed, the pharmacy may not fill the medication and the patient may miss doses or face full retail price, which can be thousands of dollars. People actively losing weight on Wegovy, or who depend on it for health reasons, should watch for these mid-course authorization requests so they can act quickly. Anyone starting or continuing on Wegovy should know that this kind of paperwork can pop up and plan for extra time around refill points. Caveats and risks: rules vary by insurer and by plan, so there’s no single answer about how strict a carrier will be. Prior authorizations are administrative, not a statement about the drug’s safety or effectiveness. The main risk for patients is interruption of medication or unexpected out-of-pocket cost. If you run into this, good steps are: contact your insurer to ask exactly what documentation they need, ask your doctor’s office to submit records promptly, and keep a printed copy of refill dates and any submission confirmations. If a claim is denied, there’s usually an appeal process; you can also ask your insurer for an expedited review if the medication is time-sensitive. Bottom line: mid-course prior authorizations for Wegovy are common and usually administrative; they can be fixed but can cause delays and extra cost if not handled quickly.
Source: r/Semaglutide